Glenmark Pharma shares up 2% after FDA grants fast track status to cancer drug
Glenmark Pharma's innovation arm, IGI, received FDA fast track designation for its myeloma therapy ISB 2001, targeting heavily pre-treated RRMM patients. The tri-specific antibody showed high response rates and a favorable safety profile in early trials. Complete results will be presented at (...)
Site référencé: The Economic Times
The Economic Times
Piyush Goyal holds trade talks with EU Commissioner, India-EU reaffirm to conclude FTA by end of 2025
2/05/2025
US stocks close higher, lifted by Microsoft, Meta earnings
2/05/2025
Trump ousts White House national security adviser Waltz, replaces him with Rubio
2/05/2025
DIIs surpass FPIs in ownership of companies listed on NSE after 22 years
2/05/2025
FPIs boost Indian equities amid tariff optimism in April
2/05/2025
Can markets defy historical trends and thrive in May amid global challenges ?
2/05/2025
